Grundium Acquires Visiopharm to Revolutionize Digital Pathology
Grundium, a Tampere-based startup known for its cutting-edge digital pathology imaging technology, has acquired Visiopharm, a Danish leader in AI-based precision pathology software. This strategic acquisition is backed by the US healthcare private equity firm, EW Healthcare Partners.
Creating a Unified Pathology Platform
The merger of Grundium’s state-of-the-art imaging platform with Visiopharm’s AI-driven precision pathology software marks a significant advancement in the field. This combination offers a comprehensive end-to-end solution tailored for diagnostic laboratories, biopharmaceutical development, and research. By integrating these capabilities, the companies aim to enhance diagnostic accuracy and improve efficiency across various medical fields.
“Precision medicine starts with precision pathology. By combining Grundium’s imaging technologies with Visiopharm’s advanced AI applications, we are creating a stronger foundation for physicians and laboratories to adopt high-value workflows and evolve them over time,” stated Mika Kuisma, CEO of Grundium. “Together, we can help make precision pathology more accessible, more convenient, and more impactful for customers around the world.”
A Legacy of Innovation
Founded in 2015 by former Nokia engineers Kimmo Alanen, Mika Kuisma, and Janne Haavisto, Grundium has been pioneering compact, high-quality digital pathology scanners for diverse environments, including healthcare, education, and research. The company’s flagship product, the Ocus® series, is acclaimed for making high-quality digital and remote pathology accessible and affordable for laboratories of all sizes.
Visiopharm, established in 2002 by Michael Grunkin and Johan Doré Hansen, is renowned for its mission to advance precision medicine through transformative image analysis. The company offers AI-based precision pathology software that supports both research and diagnostic applications. In diagnostics, Visiopharm specializes in clinical applications with nine algorithms approved under IVDR for EU customers, providing seamless integration into existing laboratory workflows.
Enhancing Precision Diagnostics
Michael Grunkin, CEO of Visiopharm, emphasized the synergy between the two companies: “Grundium and Visiopharm bring together highly complementary capabilities. This combination allows us to connect biomarker analysis, imaging, and quality management in new ways, while continuing to support the software and workflows our customers rely on today.”
The combined platform is designed to facilitate more efficient and scalable digital pathology, mitigating infrastructure barriers and reducing costs. By uniting Grundium’s scanner portfolio with Visiopharm’s AI software, the platform supports a wide array of applications, from individual laboratory workflows to enterprise-wide deployments, biomarker development, translational research, clinical studies, and companion diagnostic programs.
Previous collaborations between Grundium and Visiopharm have already demonstrated the effectiveness of their integrated solutions in laboratory settings, and this acquisition solidifies their partnership.
Impact on Global Healthcare
Andy Thomson, Operating Partner at EW Healthcare Partners and Chairman of the Board of Directors of Grundium, noted, “Digital pathology has the potential to significantly improve diagnostic accuracy, workflow efficiency, and global access to expert care. The platform we are creating brings together these capabilities to make diagnosis faster, more reliable, and more efficient, transforming patient care and supporting the development of revolutionary new treatments, particularly in oncology.”
To ensure continuity for existing customers and partners, both Grundium’s digital scanners and Visiopharm’s precision pathology software will remain supported and independently available. This flexibility allows customers to either maintain their current solutions or integrate the enhanced capabilities as their needs evolve.
For more details on this groundbreaking acquisition, visit the source: Here.
“`
